Cel-Sci other research news

CELI received a $50,000 grant from the Maryland Industrial Partnership to develop an ELISA test for HIV that measures levels of antibodies binding to HIV-1 p17 peptides in serum. CELI will optimize and evaluate the test's utility as a routine monitoring test for HIV disease progression.

The company said it expects such a test would be cheaper than the current PCR test. CEO Geert Kersten expects the test to be priced below $75-$100, which is the range for Chiron Corp.'s (CHIR) first generation branched DNA test. He added that samples won't have to be shipped for laboratory processing. ...